Patents by Inventor Erin Keaney

Erin Keaney has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Bi-heteroaryl compounds as Vps34 inhibitors
    Patent number: 8901147
    Abstract: The present invention includes novel methods of treating a disease or disorder characterized by hyperactivity of Vps34, and compound as Vps34 inhibitors; particularly compounds of Formula I: or a pharmaceutically acceptable salt thereof, as well as methods of treating a disease, disorder, or syndrome associated with Vps34 inhibition, particularly hyperproliferative diseases. The present invention also includes pharmaceutical compositions including compounds of formula I and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: February 5, 2014
    Date of Patent: December 2, 2014
    Assignee: Novartis AG
    Inventors: Ivan Cornella Taracido, Edmund Harrington, Ayako Honda, Erin Keaney
  • BI-HETEROARYL COMPOUNDS AS VPS34 INHIBITORS
    Publication number: 20140155402
    Abstract: The present invention includes novel methods of treating a disease or disorder characterized by hyperactivity of Vps34, and compound as Vps34 inhibitors; particularly compounds of Formula I: or a pharmaceutically acceptable salt thereof, as well as methods of treating a disease, disorder, or syndrome associated with Vps34 inhibition, particularly hyperproliferative diseases. The present invention also includes pharmaceutical compositions including compounds of formula I and pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: February 5, 2014
    Publication date: June 5, 2014
    Applicant: Novartis AG
    Inventors: Ivan Cornella Taracido, Edmund Harrington, Ayako Honda, Erin Keaney
  • Bi-heteroaryl compounds as Vps34 inhibitors
    Patent number: 8685993
    Abstract: The present invention includes novel methods of treating a disease or disorder characterized by hyperactivity of Vps34, and compound as Vps34 inhibitors; particularly compounds of Formula I or a pharmaceutically acceptable salt thereof, as well as methods of treating a disease, disorder, or syndrome associated with Vps34 inhibition, particularly hyperproliferative diseases. The present invention also includes pharmaceutical compositions including compounds of formula I and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: December 19, 2011
    Date of Patent: April 1, 2014
    Assignee: Novartis AG
    Inventors: Ivan Cornella Taracido, Edmund Martin Harrington, Ayako Honda, Erin Keaney
  • BI-HETEROARYL COMPOUNDS AS VPS34 INHIBITORS
    Publication number: 20130338159
    Abstract: The present invention includes novel methods of treating a disease or disorder characterized by hyperactivity of Vps34, and compound as Vps34 inhibitors; particularly compounds of Formula I or a pharmaceutically acceptable salt thereof, as well as methods of treating a disease, disorder, or syndrome associated with Vps34 inhibition, particularly hyperproliferative diseases. The present invention also includes pharmaceutical compositions including compounds of formula I and pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: December 19, 2011
    Publication date: December 19, 2013
    Applicant: NOVARTIS AG
    Inventors: Ivan Cornella Taracido, Edmund Martin Harrington, Ayako Honda, Erin Keaney
  • Selective hydroxamate based MMP inhibitors
    Patent number: 8314148
    Abstract: The present invention provides a compound of formula (I): said compound is inhibitor of MMP-9, and/or MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-9, and/or MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-9, and/or MMP-12 and/or MMP-13. Finally, the present invention also provides a pharmaceutical composition.
    Type: Grant
    Filed: May 11, 2012
    Date of Patent: November 20, 2012
    Assignee: Novartis AG
    Inventors: Thomas Leutert, Jonathan E. Grob, Ruben Alberto Tommasi, Erin Keaney, Ayako Honda